156079-58-2

Upstream product

• 2516-96-3 2-chloro-5-nitrobenzoic acid 
• 16588-15-1 2-chloro-5-nitro-benzamide 
• 16588-02-6 4-chloro-3-cyanonitrobenzene 
• 111-42-2 2,2'-iminobis[ethanol] 
• 17417-09-3 2-fluoro-5-nitrobenzonitrile 

Downstream Products

• 288250-04-4 N-{3-cyano-4-[bis(2-hydroxyethyl)amino]phenyl}-1-(4-fluorophenyl)-5-methylpyrazole-4-carboxamide 
• 398137-18-3 5-amino-2-[N,N-bis(2-hydroxyethyl)amino]benzonitrile 
• 156079-60-6 2-[Bis-(2-chloro-ethyl)-amino]-5-nitro-benzonitrile 

Relevant academic research and scientific papers

AMIDE COMPOUNDS AND MEDICINAL USE THEREOF

The present invention relates to a compound of the formula wherein R1 is substituted aryl, heteroaryl and the like, R2 and R3 are hydrogen, alkyl, halogen, hydroxyl group and the like, Q is N, CH and the like, W is hydrogen, alkyl, hydroxycarbonylalkyl and the like, X is halogen, cyano, nitro, amino and the like, X' is hydrogen, halogen, cyano, nitro, and Y is alkyl, hydroxyl group, alkoxy, mercapto and the like and a salt thereof, and a medicine containing the said compound. The compound of the present invention shows a superior inhibitory effect on activated lymphocytes proliferation and is useful as an agent for the prophylaxis or treatment of various autoimmune diseases.

Optimization of Alkylating Agent Prodrugs Derived from Phenol and Aniline Mustards: A New Clinical Candidate Prodrug (ZD2767) for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

Sixteen novel potential prodrugs derived from phenol or aniline mustards and their 16 corresponding drugs with ring substitution and/or different alkylating functionalities were designed.The 4-bis(2-bromoethyl)-(1a), 4-bis(2-iodoethyl)-(1b), and